- Home
- UAL vs BIIB Comparison
UAL vs BIIB Comparison
Compare UAL & BIIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- UAL
- BIIB
- Stock Information
- Founded
- UAL 1934
- BIIB 1978
- Country
- UAL United States
- BIIB United States
- Employees
- UAL N/A
- BIIB N/A
- Industry
- UAL Air Freight/Delivery Services
- BIIB Biotechnology: Pharmaceutical Preparations
- Sector
- UAL Consumer Discretionary
- BIIB Health Care
- Exchange
- UAL Nasdaq
- BIIB Nasdaq
- Market Cap
- UAL 31.6B
- BIIB 25.1B
- IPO Year
- UAL N/A
- BIIB 1991
- Fundamental
- Price
- UAL $101.16
- BIIB $149.02
- Analyst Decision
- UAL Strong Buy
- BIIB Buy
- Analyst Count
- UAL 16
- BIIB 26
- Target Price
- UAL $95.70
- BIIB $248.00
- AVG Volume (30 Days)
- UAL 4.9M
- BIIB 1.6M
- Earning Date
- UAL 01-21-2025
- BIIB 02-11-2025
- Dividend Yield
- UAL N/A
- BIIB N/A
- EPS Growth
- UAL N/A
- BIIB 10.05
- EPS
- UAL 8.30
- BIIB 11.06
- Revenue
- UAL $55,994,000,000.00
- BIIB $9,607,500,000.00
- Revenue This Year
- UAL $6.56
- BIIB N/A
- Revenue Next Year
- UAL $7.00
- BIIB N/A
- P/E Ratio
- UAL $12.19
- BIIB $13.47
- Revenue Growth
- UAL 6.67
- BIIB N/A
- 52 Week Low
- UAL $37.02
- BIIB $145.07
- 52 Week High
- UAL $105.09
- BIIB $268.30
- Technical
- Relative Strength Index (RSI)
- UAL 64.17
- BIIB 32.44
- Support Level
- UAL $90.17
- BIIB $145.07
- Resistance Level
- UAL $97.48
- BIIB $149.92
- Average True Range (ATR)
- UAL 3.70
- BIIB 3.81
- MACD
- UAL -0.47
- BIIB 0.05
- Stochastic Oscillator
- UAL 73.66
- BIIB 22.51
About UAL United Airlines Holdings Inc.
United Airlines is a major us network carrier with hubs in San Francisco, Chicago, Houston, Denver, Los Angeles, New York/Newark, and Washington, D.C. United operates a hub-and-spoke system that is more focused on international and long-haul travel than its large us peers.
About BIIB Biogen Inc.
Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva (oncology) and Ocrevus (multiple sclerosis) are marketed via a collaboration with Roche. Biogen markets several multiple sclerosis drugs including Plegridy, Tysabri, Tecfidera, and Vumerity. Biogen's newer products include Spinraza (SMA, with partner Ionis), Leqembi (Alzheimers, with partner Eisai), Skyclarys (Friedreich's Ataxia, Reata), Zurzuvae (postpartum depression, Sage), and Qalsody (ALS, Ionis). Biogen has several drug candidates in phase 3 trials in neurology, immunology, and rare diseases.